Photodiagnosis and Photodynamic Therapy最新文献_第4页

Associations between choroidal thickness and rate of axial elongation in orthokeratology lens users 角膜塑形镜使用者脉络膜厚度与轴向延伸率之间的关系。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2024.104450

Riping Zhang , Suoqing Zhuang , Youming Zhou , Man Pan Chin , Lixia Sun , Vishal Jhanji , Mingzhi Zhang

Objective

To investigate the impact of using orthokeratology lenses (OK lenses) for one year on the axial length (AL) and choroidal thickness (ChT) in the 6 mm concentric central retinal region.

Methods

36 myopic children (36 eyes) aged 8 to 16 years were enrolled. For the duration of one year, the OK group (18 subjects) utilized OK lenses, while the spectacles group (18 subjects) utilized single-vision spectacles as a control. Only their right eyes were used for analysis. ChT in nine regions of the retina was evaluated using optical coherence tomography. AL and other ocular parameters were measured using optical biometry. The measurements were obtained at baseline, 3 months, 6 months, and 12 months.

Results

After 12 months of treatment, the OK group showed a reduced rate of AL elongation. The first interval (baseline to 3 months) saw the most notable alteration (p < 0.0001). ChT increased in most regions after wearing OK lenses, except for the nasal retinal region. However, the alteration in nasal ChT exhibited the strongest association with the alteration in AL.

Conclusion

The efficacy of myopia control with OK lenses is most pronounced during the initial months of wear. Alterations in the thickness of the nasal choroidal region may correlate with the elongation of the AL, implying its potential role as a biomarker for assessing the efficacy of OK lenses in myopia control.

目的：探讨角膜塑形镜（OK镜片）使用一年对6mm同心视网膜中央区域轴向长度（AL）和脉络膜厚度（ChT）的影响。方法：选取8 ~ 16岁近视儿童36例（36眼）。在一年的时间里，OK组（18名受试者）使用OK镜片，而眼镜组（18名受试者）使用单视力眼镜作为对照。只有他们的右眼被用于分析。使用光学相干断层扫描评估视网膜九个区域的ChT。采用光学生物计量法测定AL及其他眼部参数。在基线、3个月、6个月和12个月时进行测量。结果：治疗12个月后，OK组AL伸长率降低。第一个时间间隔（基线至3个月）变化最为显著（p < 0.0001）。除鼻视网膜区域外，佩戴OK隐形眼镜后大部分区域的ChT均增加。结论：在佩戴OK隐形眼镜的最初几个月，其控制近视的效果最为明显。鼻脉络膜厚度的改变可能与AL的伸长有关，这意味着它可能作为评估OK隐形眼镜控制近视效果的生物标志物。

{"title":"Associations between choroidal thickness and rate of axial elongation in orthokeratology lens users","authors":"Riping Zhang , Suoqing Zhuang , Youming Zhou , Man Pan Chin , Lixia Sun , Vishal Jhanji , Mingzhi Zhang","doi":"10.1016/j.pdpdt.2024.104450","DOIUrl":"10.1016/j.pdpdt.2024.104450","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the impact of using orthokeratology lenses (OK lenses) for one year on the axial length (AL) and choroidal thickness (ChT) in the 6 mm concentric central retinal region.</div></div><div><h3>Methods</h3><div>36 myopic children (36 eyes) aged 8 to 16 years were enrolled. For the duration of one year, the OK group (18 subjects) utilized OK lenses, while the spectacles group (18 subjects) utilized single-vision spectacles as a control. Only their right eyes were used for analysis. ChT in nine regions of the retina was evaluated using optical coherence tomography. AL and other ocular parameters were measured using optical biometry. The measurements were obtained at baseline, 3 months, 6 months, and 12 months.</div></div><div><h3>Results</h3><div>After 12 months of treatment, the OK group showed a reduced rate of AL elongation. The first interval (baseline to 3 months) saw the most notable alteration (<em>p</em> < 0.0001). ChT increased in most regions after wearing OK lenses, except for the nasal retinal region. However, the alteration in nasal ChT exhibited the strongest association with the alteration in AL.</div></div><div><h3>Conclusion</h3><div>The efficacy of myopia control with OK lenses is most pronounced during the initial months of wear. Alterations in the thickness of the nasal choroidal region may correlate with the elongation of the AL, implying its potential role as a biomarker for assessing the efficacy of OK lenses in myopia control.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104450"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematoporphyrin derivative-photodynamic therapy (HpD-PDT) for extensive vulvar and vaginal Bowen's disease: A case report 血卟啉衍生物光动力疗法（HpD-PDT）治疗广泛外阴和阴道鲍文氏病1例报告。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2024.104465

Xiaoqing Xiang , Yanliang Li , Can Shi , Runqun Liu , Guozhang Ma , Yunyun Cao , Lianheng Xia , Jie Gao

Bowen's disease (BD) is an intraepithelial squamous cell carcinoma (SCC) that commonly affects older individuals, with the vulva being a prevalent site in women. Lesions within the vagina pose a particular challenge for surgical treatment, often compromising both functional integrity and cosmesis. Photodynamic therapy (PDT) is an emerging, safe, and non-invasive technique utilizing a photosensitizer and a specific light source, widely applied in the treatment of malignancies and skin diseases. We report the case of a 74-year-old woman presenting with a large, dark brown patch on the vulva, histopathologically confirmed as BD. The patient also had lesions within the vagina. Hematoporphyrin derivative-photodynamic therapy (HpD-PDT) was administered, with an optical fiber used for targeted treatment of the vaginal lesions. Complete resolution of the lesions was observed after a single treatment. A follow-up biopsy at 7 months post-treatment revealed no residual tumor cells. The patient remains disease-free at 2 years follow-up and continues to be monitored. This case suggests that HpD-PDT is a viable treatment option for BD, and may be particularly advantageous for elderly patients with extensive or vaginally located lesions, where preserving function and cosmesis is paramount.

鲍恩氏病（BD）是一种上皮内鳞状细胞癌（SCC），常见于老年人，外阴是女性的常见部位。阴道内病变对手术治疗提出了特别的挑战，通常会损害功能完整性和美容。光动力疗法（PDT）是一种新兴的、安全的、无创的利用光敏剂和特定光源的技术，广泛应用于恶性肿瘤和皮肤病的治疗。我们报告一例74岁女性外阴出现大的深棕色斑块，组织病理学证实为BD。患者阴道内也有病变。采用血卟啉衍生物光动力疗法（HpD-PDT），光纤用于阴道病变的靶向治疗。在一次治疗后，观察到病变完全消退。治疗后7个月的随访活检显示没有残留的肿瘤细胞。在2年的随访中，患者仍无疾病，并继续接受监测。本病例提示HpD-PDT是BD的一种可行的治疗选择，对于广泛或阴道病变的老年患者尤其有利，在这些患者中，保留功能和美容是最重要的。

{"title":"Hematoporphyrin derivative-photodynamic therapy (HpD-PDT) for extensive vulvar and vaginal Bowen's disease: A case report","authors":"Xiaoqing Xiang , Yanliang Li , Can Shi , Runqun Liu , Guozhang Ma , Yunyun Cao , Lianheng Xia , Jie Gao","doi":"10.1016/j.pdpdt.2024.104465","DOIUrl":"10.1016/j.pdpdt.2024.104465","url":null,"abstract":"<div><div>Bowen's disease (BD) is an intraepithelial squamous cell carcinoma (SCC) that commonly affects older individuals, with the vulva being a prevalent site in women. Lesions within the vagina pose a particular challenge for surgical treatment, often compromising both functional integrity and cosmesis. Photodynamic therapy (PDT) is an emerging, safe, and non-invasive technique utilizing a photosensitizer and a specific light source, widely applied in the treatment of malignancies and skin diseases. We report the case of a 74-year-old woman presenting with a large, dark brown patch on the vulva, histopathologically confirmed as BD. The patient also had lesions within the vagina. Hematoporphyrin derivative-photodynamic therapy (HpD-PDT) was administered, with an optical fiber used for targeted treatment of the vaginal lesions. Complete resolution of the lesions was observed after a single treatment. A follow-up biopsy at 7 months post-treatment revealed no residual tumor cells. The patient remains disease-free at 2 years follow-up and continues to be monitored. This case suggests that HpD-PDT is a viable treatment option for BD, and may be particularly advantageous for elderly patients with extensive or vaginally located lesions, where preserving function and cosmesis is paramount.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104465"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optic nerve head changes in acute central serous chorioretinopathy: Implications for glaucoma risk 急性中心性浆液性脉络膜视网膜病变的视神经头变化：对青光眼风险的影响。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2025.104478

Esma Ecem Ersoy, Ebubekir Durmuş

Objective

Imaging techniques have demonstrated changes in the choroid and retina in acute central serous chorioretinopathy (CSCR), but the effects on the optic nerve head (ONH) remain unclear. This study investigates ONH structural changes in acute CSCR using enhanced deep imaging optical coherence tomography (EDI-OCT).

Methods

A prospective cohort study included 51 acute CSCR patients and 51 healthy controls aged 18–65 years. Patients had symptoms for less than three months, with no prior treatment or ocular pathology. Participants with refractive errors of ±6D spherical or less and ±3D cylindrical or less were included, while with optic nerve/choroidal conditions, corticosteroid use, systemic diseases like sleep apnea, and media opacities were excluded. Comprehensive eye exams and EDI-OCT were performed to evaluate retinal, choroidal, and ONH parameters.

Results

The mean subfoveal choroidal thickness (SFCT) (434.51±95.45 µm vs. 289.55±87.21 µm) and peripapillary choroidal thickness (PPCT) (282.12±79.14 µm vs. 180.79±53.99 µm) were significantly higher in the CSCR group compared to controls (p < 0.001 for both). Retinal nerve fiber layer (RNFL) (107.14±15.15 µm vs. 101.06±14.31 µm, p = 0.04) and lamina cribrosa thickness (LCT) (307.14±63.83 µm vs. 200.04±54.23 µm, p < 0.001) were significantly higher, while anterior laminar depth (ALD) and Bruch's membran opening-minimum rim width (BMO-MRW) were significantly lower in the acute CSCR.

Conclusion

In acute CSCR, increased SFCT is accompanied by a corresponding rise in PPCT, leading to significant ONH structural changes and enhanced blood flow, potentially offering glaucoma protection. However, further research is needed to explore the long-term effects of chronic CSCR on choriocapillaris ischemia and optic nerve.

目的：成像技术已经证实了急性中心性浆液性脉络膜视网膜病变（CSCR）中脉络膜和视网膜的变化，但对视神经头（ONH）的影响仍不清楚。本研究使用增强型深部成像光学相干断层扫描（EDI-OCT）研究急性中心性浆液性脉络膜视网膜病变中视神经头结构的变化：一项前瞻性队列研究纳入了 51 名急性 CSCR 患者和 51 名健康对照者，年龄在 18-65 岁之间。患者症状持续时间少于三个月，之前未接受过任何治疗或眼部病变。研究对象包括屈光不正为±6D球面或以下和±3D柱面或以下的患者，但不包括视神经/脉络膜病变、使用皮质类固醇、患有睡眠呼吸暂停等全身性疾病和介质不透明的患者。研究人员进行了全面的眼部检查和 EDI-OCT 检查，以评估视网膜、脉络膜和 ONH 参数：结果：与对照组相比，CSCR 组的平均视网膜下脉络膜厚度（SFCT）（434.51±95.45 µm vs. 289.55±87.21 µm）和毛细血管周围脉络膜厚度（PPCT）（282.12±79.14 µm vs. 180.79±53.99 µm）显著增加（p结论：在急性 CSCR 中，SFCT 的增加伴随着 PPCT 的相应升高，从而导致 ONH 结构的显著变化和血流的增强，这有可能为青光眼提供保护。然而，还需要进一步研究慢性 CSCR 对绒毛膜缺血和视神经的长期影响。

{"title":"Optic nerve head changes in acute central serous chorioretinopathy: Implications for glaucoma risk","authors":"Esma Ecem Ersoy, Ebubekir Durmuş","doi":"10.1016/j.pdpdt.2025.104478","DOIUrl":"10.1016/j.pdpdt.2025.104478","url":null,"abstract":"<div><h3>Objective</h3><div>Imaging techniques have demonstrated changes in the choroid and retina in acute central serous chorioretinopathy (CSCR), but the effects on the optic nerve head (ONH) remain unclear. This study investigates ONH structural changes in acute CSCR using enhanced deep imaging optical coherence tomography (EDI-OCT).</div></div><div><h3>Methods</h3><div>A prospective cohort study included 51 acute CSCR patients and 51 healthy controls aged 18–65 years. Patients had symptoms for less than three months, with no prior treatment or ocular pathology. Participants with refractive errors of ±6D spherical or less and ±3D cylindrical or less were included, while with optic nerve/choroidal conditions, corticosteroid use, systemic diseases like sleep apnea, and media opacities were excluded. Comprehensive eye exams and EDI-OCT were performed to evaluate retinal, choroidal, and ONH parameters.</div></div><div><h3>Results</h3><div>The mean subfoveal choroidal thickness (SFCT) (434.51±95.45 µm vs. 289.55±87.21 µm) and peripapillary choroidal thickness (PPCT) (282.12±79.14 µm vs. 180.79±53.99 µm) were significantly higher in the CSCR group compared to controls (<em>p</em> < 0.001 for both). Retinal nerve fiber layer (RNFL) (107.14±15.15 µm vs. 101.06±14.31 µm, <em>p</em> = 0.04) and lamina cribrosa thickness (LCT) (307.14±63.83 µm vs. 200.04±54.23 µm, <em>p</em> < 0.001) were significantly higher, while anterior laminar depth (ALD) and Bruch's membran opening-minimum rim width (BMO-MRW) were significantly lower in the acute CSCR.</div></div><div><h3>Conclusion</h3><div>In acute CSCR, increased SFCT is accompanied by a corresponding rise in PPCT, leading to significant ONH structural changes and enhanced blood flow, potentially offering glaucoma protection. However, further research is needed to explore the long-term effects of chronic CSCR on choriocapillaris ischemia and optic nerve.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104478"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema 红色（670 nm）阈下微脉冲激光治疗与玻璃体内注射阿布西普治疗treatment-naïve糖尿病性黄斑水肿的一年实际疗效比较

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2025.104484

Kai Ching Peter Leung, Sunny, Chi Lik Au

引用次数: 0

Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life 现实生活中基底细胞癌和Bowen病对光动力治疗反应的肿瘤、间质和糖溶标志物分析。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2024.104442

L Bernal-Masferrer , T Gracia-Cazaña , L Najera-Botello , MC Gomez-Mateo , P Cerro , MC Matei , M Gallego-Rentero , S González , A Juarranz , Y Gilaberte

Background

Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study investigates the clinical, histological, and molecular factors that affect the efficacy of methyl aminolevulinate PDT (MAL-PDT) for BCC and BD.

Methods and Patients

Prospective observational multicentric study performed between May 2019 and January 2021 with 64 patients included. Clinical data such as tumor thickness, location, and histological subtype were recorded. Immunohistochemical analysis was performed on tumor samples to assess the expression of biomarkers including p53, β-catenin, and GLUT1.

Results

Tumor thickness was found to be a critical determinant of MAL-PDT response, with thicker nodular BCCs showing reduced response rates compared to thinner, superficial BCCs and BD lesions. Immunohistochemical analysis revealed that p53 positivity was associated with better treatment outcomes, while increased β-catenin and cytoplasmic GLUT1 expression correlated with resistance to PDT. On the other hand, the metabolic profile of the tumors indicated that tumors with higher glycolytic activity were less responsive to treatment, therefore, using metformin, a glycolytic inhibitor, as a potential adjuvant therapy to improve outcomes in resistant tumors should be considered.

Conclusion

This study emphasizes the importance of personalized approaches in the use of MAL-PDT, tailoring treatment according to tumor-specific characteristics. Biomarkers such as p53, β-catenin, and GLUT1 can serve as predictive tools for PDT response, helping clinicians identify patients who may benefit from alternative or combined treatments to enhance therapeutic efficacy.

背景：光动力疗法（PDT）是一种广泛应用于非黑色素瘤皮肤癌的非手术治疗方法，包括基底细胞癌（BCC）、光化性角化病（AK）和Bowen病（BD）。PDT有很高的成功率，但各种因素会影响治疗反应。本研究探讨了影响甲基氨基乙酰丙酸PDT （MAL-PDT）治疗BCC和bd疗效的临床、组织学和分子因素。方法和患者：2019年5月至2021年1月，纳入64例患者的前瞻性观察性多中心研究。记录肿瘤的厚度、位置、组织学亚型等临床资料。对肿瘤样本进行免疫组织化学分析，以评估生物标志物的表达，包括p53、β-catenin和GLUT1。结果：肿瘤厚度被发现是MAL-PDT反应的关键决定因素，较厚的结节性bcc与较薄的浅表bcc和BD病变相比，反应率较低。免疫组织化学分析显示p53阳性与更好的治疗结果相关，而β-catenin和细胞质GLUT1表达增加与PDT耐药相关。另一方面，肿瘤的代谢特征表明糖酵解活性较高的肿瘤对治疗反应较差，因此，应考虑使用糖酵解抑制剂二甲双胍作为潜在的辅助治疗来改善耐药肿瘤的预后。结论：本研究强调了使用MAL-PDT的个性化方法的重要性，根据肿瘤特异性特征定制治疗。生物标志物如p53、β-catenin和GLUT1可以作为PDT反应的预测工具，帮助临床医生识别可能受益于替代或联合治疗的患者，以提高治疗效果。

{"title":"Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life","authors":"L Bernal-Masferrer , T Gracia-Cazaña , L Najera-Botello , MC Gomez-Mateo , P Cerro , MC Matei , M Gallego-Rentero , S González , A Juarranz , Y Gilaberte","doi":"10.1016/j.pdpdt.2024.104442","DOIUrl":"10.1016/j.pdpdt.2024.104442","url":null,"abstract":"<div><h3>Background</h3><div>Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study investigates the clinical, histological, and molecular factors that affect the efficacy of methyl aminolevulinate PDT (MAL-PDT) for BCC and BD.</div></div><div><h3>Methods and Patients</h3><div>Prospective observational multicentric study performed between May 2019 and January 2021 with 64 patients included. Clinical data such as tumor thickness, location, and histological subtype were recorded. Immunohistochemical analysis was performed on tumor samples to assess the expression of biomarkers including p53, β-catenin, and GLUT1.</div></div><div><h3>Results</h3><div>Tumor thickness was found to be a critical determinant of MAL-PDT response, with thicker nodular BCCs showing reduced response rates compared to thinner, superficial BCCs and BD lesions. Immunohistochemical analysis revealed that p53 positivity was associated with better treatment outcomes, while increased β-catenin and cytoplasmic GLUT1 expression correlated with resistance to PDT. On the other hand, the metabolic profile of the tumors indicated that tumors with higher glycolytic activity were less responsive to treatment, therefore, using metformin, a glycolytic inhibitor, as a potential adjuvant therapy to improve outcomes in resistant tumors should be considered.</div></div><div><h3>Conclusion</h3><div>This study emphasizes the importance of personalized approaches in the use of MAL-PDT, tailoring treatment according to tumor-specific characteristics. Biomarkers such as p53, β-catenin, and GLUT1 can serve as predictive tools for PDT response, helping clinicians identify patients who may benefit from alternative or combined treatments to enhance therapeutic efficacy.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104442"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Umbrella review of adjuvant photodynamic therapy for cholangiocarcinoma palliative treatment

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2025.104472

Hanhan Chen , Honglin Li , Huijie Li , Zhen Zhang

Background

Cholangiocarcinoma is a rare and often fatal malignancy. Numerous studies have demonstrated promising outcomes and survival rates associated with adjuvant photodynamic therapy (PDT) in the palliative treatment of cholangiocarcinoma.

Objective

To systematically evaluate the existing meta-analyses on PDT for cholangiocarcinoma, assessing evidence quality and strength while performing updated meta-analyses to refine survival outcomes.

Methods

PubMed, EMBASE, Cochrane Library, and Web of Science were systematically searched up to September 18, 2024, to identify meta-analyses and clinical studies on PDT in patients with cholangiocarcinoma. The random-effects model was employed to re-synthesize existing meta-analyses, with a comprehensive evaluation of methodological quality. Updated meta-analyses of survival data were conducted, including subgroup analyses stratified by cholangiocarcinoma type and intervention modality.

Results

A total of 5 meta-analyses and 21 clinical studies were included. The findings indicated that combining PDT with stenting or chemotherapy can significantly improve overall survival in patients with cholangiocarcinoma and reduce mortality rate, without increasing the risk of adverse events (AEs) such as cholangitis or abscess formation. For extrahepatic cholangiocarcinoma, adding PDT to stenting demonstrated a notable improvement in the 2-year survival rate. Meanwhile, for hilar cholangiocarcinoma, the addition of chemotherapy to PDT showed a more pronounced enhancement in the 1-year survival rate.

Conclusion

Current evidence indicates that PDT combined with stenting or chemotherapy in the palliative treatment of cholangiocarcinoma decreases overall mortality and enhances OS without increasing the incidence of AEs. Adding PDT to stenting or chemotherapy may be more beneficial for long-term efficacy.

{"title":"Umbrella review of adjuvant photodynamic therapy for cholangiocarcinoma palliative treatment","authors":"Hanhan Chen , Honglin Li , Huijie Li , Zhen Zhang","doi":"10.1016/j.pdpdt.2025.104472","DOIUrl":"10.1016/j.pdpdt.2025.104472","url":null,"abstract":"<div><h3>Background</h3><div>Cholangiocarcinoma is a rare and often fatal malignancy. Numerous studies have demonstrated promising outcomes and survival rates associated with adjuvant photodynamic therapy (PDT) in the palliative treatment of cholangiocarcinoma.</div></div><div><h3>Objective</h3><div>To systematically evaluate the existing meta-analyses on PDT for cholangiocarcinoma, assessing evidence quality and strength while performing updated meta-analyses to refine survival outcomes.</div></div><div><h3>Methods</h3><div>PubMed, EMBASE, Cochrane Library, and Web of Science were systematically searched up to September 18, 2024, to identify meta-analyses and clinical studies on PDT in patients with cholangiocarcinoma. The random-effects model was employed to re-synthesize existing meta-analyses, with a comprehensive evaluation of methodological quality. Updated meta-analyses of survival data were conducted, including subgroup analyses stratified by cholangiocarcinoma type and intervention modality.</div></div><div><h3>Results</h3><div>A total of 5 meta-analyses and 21 clinical studies were included. The findings indicated that combining PDT with stenting or chemotherapy can significantly improve overall survival in patients with cholangiocarcinoma and reduce mortality rate, without increasing the risk of adverse events (AEs) such as cholangitis or abscess formation. For extrahepatic cholangiocarcinoma, adding PDT to stenting demonstrated a notable improvement in the 2-year survival rate. Meanwhile, for hilar cholangiocarcinoma, the addition of chemotherapy to PDT showed a more pronounced enhancement in the 1-year survival rate.</div></div><div><h3>Conclusion</h3><div>Current evidence indicates that PDT combined with stenting or chemotherapy in the palliative treatment of cholangiocarcinoma decreases overall mortality and enhances OS without increasing the incidence of AEs. Adding PDT to stenting or chemotherapy may be more beneficial for long-term efficacy.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104472"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical riboflavin versus 5-aminolevulinic acid photodynamic therapy for the treatment of mild to moderate acne: A split-face randomized study 局部核黄素与5-氨基乙酰丙酸光动力疗法治疗轻度至中度痤疮：一项裂脸随机研究。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2024.104449

Aijia Ding , Li Shi , Feng Jiang , Chong Wang , Jianglin Zhang

Background

ALA-PDT has been widely used in mild to moderate acne vulgaris worldwide. However, very few studies used riboflavin-PDT to treat acne vulgaris.

Objective

To investigate the efficacy and adverse events of riboflavin-PDT to treat mild to moderate facial acne, and compare it with ALA-PDT on a non-inferiority basis.

Methods

33 eligible patients were enrolled, and 30 patients completed follow-up. Either side of the face was assigned randomly to riboflavin or ALA blue-light-PDT. Patients received 3 sessions of PDT in 1-week intervals and were followed up at weeks 4, 6, and 10.

Results

Both ALA and riboflavin-PDT significantly reduced non-inflammatory and inflammatory lesions at weeks 4, 6, and 10 compared to baseline (P all <0.001). For the primary outcome, the difference in the improvement rate of total lesions between the Ribo and ALA side was 2.6 % (-4.3 %, 12.5 %; p = 0.71), which didn't reach the inferiority margin. Patients described greater in-treatment pain and burning sensation (P < 0.001), more prominent post-treatment erythema (P = 0.003), hyperpigmentation (P < 0.001), and desquamation (P = 0.006) on the ALA side than on riboflavin side.

Conclusion

The efficacy of riboflavin-PDT was comparable to that of blue-light ALA-PDT in treating mild to moderate acne vulgaris. Riboflavin-PDT had fewer in-treatment and post-treatment adverse events than ALA-PDT.

背景：ALA-PDT在世界范围内广泛应用于轻中度寻常性痤疮。然而，很少有研究使用核黄素- pdt治疗寻常性痤疮。目的：探讨核黄素- pdt治疗轻、中度面部痤疮的疗效及不良反应，并与ALA-PDT进行非劣效性比较。方法：33例符合条件的患者入组，30例患者完成随访。面部两侧随机分配核黄素或ALA蓝光pdt。患者每隔1周接受3次PDT治疗，并在第4、6和10周进行随访。结果：与基线相比，ALA和核黄素- pdt在第4周、第6周和第10周均显著减少非炎性和炎性病变（P均）。结论：核黄素- pdt治疗轻中度寻常性痤疮的疗效与蓝光ALA- pdt相当。与ALA-PDT相比，核黄素- pdt治疗期间和治疗后的不良事件较少。

{"title":"Topical riboflavin versus 5-aminolevulinic acid photodynamic therapy for the treatment of mild to moderate acne: A split-face randomized study","authors":"Aijia Ding , Li Shi , Feng Jiang , Chong Wang , Jianglin Zhang","doi":"10.1016/j.pdpdt.2024.104449","DOIUrl":"10.1016/j.pdpdt.2024.104449","url":null,"abstract":"<div><h3>Background</h3><div>ALA-PDT has been widely used in mild to moderate acne vulgaris worldwide. However, very few studies used riboflavin-PDT to treat acne vulgaris.</div></div><div><h3>Objective</h3><div>To investigate the efficacy and adverse events of riboflavin-PDT to treat mild to moderate facial acne, and compare it with ALA-PDT on a non-inferiority basis.</div></div><div><h3>Methods</h3><div>33 eligible patients were enrolled, and 30 patients completed follow-up. Either side of the face was assigned randomly to riboflavin or ALA blue-light-PDT. Patients received 3 sessions of PDT in 1-week intervals and were followed up at weeks 4, 6, and 10.</div></div><div><h3>Results</h3><div>Both ALA and riboflavin-PDT significantly reduced non-inflammatory and inflammatory lesions at weeks 4, 6, and 10 compared to baseline (P all <0.001). For the primary outcome, the difference in the improvement rate of total lesions between the Ribo and ALA side was 2.6 % (-4.3 %, 12.5 %; <em>p</em> = 0.71), which didn't reach the inferiority margin. Patients described greater in-treatment pain and burning sensation (<em>P</em> < 0.001), more prominent post-treatment erythema (<em>P</em> = 0.003), hyperpigmentation (<em>P</em> < 0.001), and desquamation (<em>P</em> = 0.006) on the ALA side than on riboflavin side.</div></div><div><h3>Conclusion</h3><div>The efficacy of riboflavin-PDT was comparable to that of blue-light ALA-PDT in treating mild to moderate acne vulgaris. Riboflavin-PDT had fewer in-treatment and post-treatment adverse events than ALA-PDT.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104449"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Choroidal vascular parameters in ocular rosacea patients 眼红斑痤疮患者脉络膜血管参数。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2024.104468

Mariagrazia Avella, Isabella Pellegrino

引用次数: 0

Effect of photodynamic therapy on vaginal intraepithelial neoplasia grade one: A retrospective cohort study 光动力疗法对阴道上皮内瘤变1级的影响：一项回顾性队列研究。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2025.104486

Yao Yang , Dan Cao , Yi Chen, Ying Xu, Zhenhong Xiong, Zhengrong Zhang, Dan Wu

Objective

To evaluate the efficacy of photodynamic therapy (PDT) for vaginal intraepithelial neoplasia grade 1 (VaIN1) related to high-risk (Hr)-human papillomavirus (HPV).

Methods

Participants aged 25–65 years treated for VaIN1 between March 2022 and September 2022 were retrospectively analyzed into three groups. The PDT and follow-up groups were matched 1:1 for gravidity, HPV type, and quadrants involved. The PDT and CO₂ laser groups were compared without matching. Patients were followed up at 6, 12, and 24 months.

Results

After matched, the lesion and Hr-HPV clearance rates of the PDT group (89.5%, 89.5%, 92.1%, and 81.6%, 84.2%, 89.5%) were significantly higher than those of the follow-up group (31.6%, 50.0%, 63.2%, and 21.1%, 26.3%, 31.6%, P < 0.05) at 6, 12, and 24 months. But the lesion clearance rates did not differ significantly between the PDT (68.9%, 82.2%, and 91.1%) and CO₂ laser groups (68.7%, 78.3%, and 85.5%, P > 0.05) at 6, 12, and 24 months, and so did Hr-HPV clearance rates (PDT as 62.2% and 77.8%, and CO₂ laser 54.2% and 61.4%, respectively, P > 0.05) at 6 and 12 months. However, at 24 months, the Hr-HPV clearance rate was higher in the PDT group than in the CO₂ laser group (86.7% vs 71.1%, P = 0.047). In the PDT group, none of the lesions progressed.

Conclusions

Compared with CO₂ laser, PDT resulted in a higher Hr-HPV clearance, as well as a low risk of complications and disease progression. PDT is an effective and noninvasive treatment for VaIN1.

目的：评价光动力疗法（PDT）治疗高危（Hr）人乳头瘤病毒（HPV）相关阴道上皮内瘤变1级（VaIN1）的疗效。方法：回顾性分析2022年3月至2022年9月期间接受VaIN1治疗的25-65岁参与者，分为三组。PDT组和随访组在妊娠、HPV类型和涉及的象限方面按1:1匹配。PDT组与CO2激光组进行不匹配比较。随访时间分别为6、12、24个月。结果：配对后，PDT组6、12、24个月病变清除率和Hr-HPV清除率（89.5%、89.5%、92.1%、81.6%、84.2%、89.5%）显著高于随访组（31.6%、50.0%、63.2%、21.1%、26.3%、31.6%），P2激光组（68.7%、78.3%、85.5%，P>0.05）， 6、12个月Hr-HPV清除率（PDT组62.2%、77.8%，CO2激光组54.2%、61.4%，P>0.05）显著高于PDT组（P >0.05）。然而，在24个月时，PDT组的Hr-HPV清除率高于CO2激光组（86.7% vs 71.1%， P=0.047）。在PDT组中，没有任何病变进展。结论：与CO2激光相比，PDT导致更高的Hr-HPV清除率，并发症和疾病进展的风险较低。PDT是一种有效的无创治疗VaIN1的方法。

{"title":"Effect of photodynamic therapy on vaginal intraepithelial neoplasia grade one: A retrospective cohort study","authors":"Yao Yang , Dan Cao , Yi Chen, Ying Xu, Zhenhong Xiong, Zhengrong Zhang, Dan Wu","doi":"10.1016/j.pdpdt.2025.104486","DOIUrl":"10.1016/j.pdpdt.2025.104486","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy of photodynamic therapy (PDT) for vaginal intraepithelial neoplasia grade 1 (VaIN1) related to high-risk (Hr)-human papillomavirus (HPV).</div></div><div><h3>Methods</h3><div>Participants aged 25–65 years treated for VaIN1 between March 2022 and September 2022 were retrospectively analyzed into three groups. The PDT and follow-up groups were matched 1:1 for gravidity, HPV type, and quadrants involved. The PDT and CO<sub>2</sub> laser groups were compared without matching. Patients were followed up at 6, 12, and 24 months.</div></div><div><h3>Results</h3><div>After matched, the lesion and Hr-HPV clearance rates of the PDT group (89.5%, 89.5%, 92.1%, and 81.6%, 84.2%, 89.5%) were significantly higher than those of the follow-up group (31.6%, 50.0%, 63.2%, and 21.1%, 26.3%, 31.6%, <em>P</em> < 0.05) at 6, 12, and 24 months. But the lesion clearance rates did not differ significantly between the PDT (68.9%, 82.2%, and 91.1%) and CO<sub>2</sub> laser groups (68.7%, 78.3%, and 85.5%, <em>P</em> > 0.05) at 6, 12, and 24 months, and so did Hr-HPV clearance rates (PDT as 62.2% and 77.8%, and CO<sub>2</sub> laser 54.2% and 61.4%, respectively, <em>P</em> > 0.05) at 6 and 12 months. However, at 24 months, the Hr-HPV clearance rate was higher in the PDT group than in the CO<sub>2</sub> laser group (86.7% vs 71.1%, <em>P</em> = 0.047). In the PDT group, none of the lesions progressed.</div></div><div><h3>Conclusions</h3><div>Compared with CO<sub>2</sub> laser, PDT resulted in a higher Hr-HPV clearance, as well as a low risk of complications and disease progression. PDT is an effective and noninvasive treatment for VaIN1.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104486"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

‘Photodynamic therapy light’: An enhanced treatment protocol for actinic keratoses with minimal pain and optimal clinical outcome by combining laser-assisted low irradiance PDT with shortened daylight PDT 光动力疗法光"：通过将激光辅助低辐照度光动力疗法与缩短日光光动力疗法相结合，改进了光化性角化病的治疗方案，使疼痛最小，临床疗效最佳。

IF 3.1 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy

Pub Date : 2025-02-01 DOI: 10.1016/j.pdpdt.2024.104372

Martin T. Braun , Kelly Del Tredici , Anna Wölling , Luitgard Wiest

Background

Between 2003 and 2016, 546 patients in our clinic discontinued outpatient treatment for actinic keratoses (AKs) using conventional photodynamic therapy (PDT) because of intolerable pain, thereby necessitating the use of a less painful procedure. Therefore, we developed a novel off-label PDT protocol: ‘PDT light’.

Methods

Laser-assisted low irradiance PDT (li-PDT) was performed beginning in 2014. The dosage was gradually lowered to 8–12 J/cm² in 2018, so that we achieved considerable pain reduction while maintaining comparable therapeutic efficacy. A further considerable reduction in pain was achieved from 2018 onwards by combining the advantages of li-PDT with daylight PDT (DLPDT), thereby resulting in 2018 in the new technique ‘PDT light’. Patients with AK Olsen grades 1 or 2 and field cancerization initially received a mild-fractionated CO2 laser pretreatment prior to MAL-incubation (methyl aminolaevulinate, Metvix ®) under occlusion for 1.5–3 h. Then, patients were illuminated on average for 1.02 min with the Aktilite-LED and, after application of an UV-screen on the illuminated area, sent out into daylight for 1 h.

Results

Between March and November 2019, we successfully treated 152 cases using the enhanced ‘PDT light’ procedure, with 137 cases achieving at follow-up 1 (on average after 8.14 months) good-to-excellent clearance rates (CLA and CLB together 90 %) and minimal adverse effects.

Conclusions

The novel ‘PDT light’ protocol proved to be an excellent and nearly painless method with an average visual-analogue scale (VAS) score of 1.19. Additional advantages included reduced illumination time, shorter outpatient stays in the clinic, fewer adverse effects, and better patient compliance than with DLPDT alone.

背景：2003 年至 2016 年间，我们诊所有 546 名患者因无法忍受疼痛而中断了使用传统光动力疗法（PDT）对光化性角化病（AKs）的门诊治疗，因此有必要使用一种痛苦较小的治疗方法。因此，我们开发了一种新颖的标签外光动力疗法方案--"光动力疗法光"：方法：方法：从 2014 年开始进行激光辅助低辐照度 PDT（li-PDT）治疗。2018年，剂量逐渐降低到8-12 J/cm²，这样我们在保持相当疗效的同时，疼痛也大大减轻了。从2018年起，通过将li-PDT的优势与日光PDT（DLPDT）相结合，进一步显著减轻了疼痛，从而在2018年形成了新技术 "光PDT"。AK奥尔森1级或2级和视野癌化的患者首先接受轻度分次CO2激光预处理，然后在闭塞状态下进行1.5-3小时的MAL-孵育（氨基乙酰乙酸甲酯，Metvix ®）。然后，用Aktilite-LED对患者进行平均1.02分钟的照射，并在照射区域涂上紫外线屏后，将患者送出日光下照射1小时：在 2019 年 3 月至 11 月期间，我们使用增强型 "PDT 光 "程序成功治疗了 152 例患者，其中 137 例患者在随访 1 期（平均 8.14 个月后）达到良好至卓越的清除率（CLA 和 CLB 合计 90%），不良反应极少：新颖的 "PDT 光 "方案被证明是一种出色且几乎无痛的方法，平均视觉模拟量表（VAS）评分为 1.19。与单独使用 DLPDT 相比，该疗法还具有照明时间短、门诊停留时间短、不良反应少、患者依从性好等优点。

{"title":"‘Photodynamic therapy light’: An enhanced treatment protocol for actinic keratoses with minimal pain and optimal clinical outcome by combining laser-assisted low irradiance PDT with shortened daylight PDT","authors":"Martin T. Braun , Kelly Del Tredici , Anna Wölling , Luitgard Wiest","doi":"10.1016/j.pdpdt.2024.104372","DOIUrl":"10.1016/j.pdpdt.2024.104372","url":null,"abstract":"<div><h3>Background</h3><div>Between 2003 and 2016, 546 patients in our clinic discontinued outpatient treatment for actinic keratoses (AKs) using conventional photodynamic therapy (PDT) because of intolerable pain, thereby necessitating the use of a less painful procedure. Therefore, we developed a novel off-label PDT protocol: ‘PDT light’.</div></div><div><h3>Methods</h3><div>Laser-assisted low irradiance PDT (li-PDT) was performed beginning in 2014. The dosage was gradually lowered to 8–12 <em>J</em>/cm² in 2018, so that we achieved considerable pain reduction while maintaining comparable therapeutic efficacy. A further considerable reduction in pain was achieved from 2018 onwards by combining the advantages of li-PDT with daylight PDT (DLPDT), thereby resulting in 2018 in the new technique ‘PDT light’. Patients with AK Olsen grades 1 or 2 and field cancerization initially received a mild-fractionated CO2 laser pretreatment prior to MAL-incubation (methyl aminolaevulinate, Metvix ®) under occlusion for 1.5–3 h. Then, patients were illuminated on average for 1.02 min with the Aktilite-LED and, after application of an UV-screen on the illuminated area, sent out into daylight for 1 h.</div></div><div><h3>Results</h3><div>Between March and November 2019, we successfully treated 152 cases using the enhanced ‘PDT light’ procedure, with 137 cases achieving at follow-up 1 (on average after 8.14 months) good-to-excellent clearance rates (CLA and CLB together 90 %) and minimal adverse effects.</div></div><div><h3>Conclusions</h3><div>The novel ‘PDT light’ protocol proved to be an excellent and nearly painless method with an average visual-analogue scale (VAS) score of 1.19. Additional advantages included reduced illumination time, shorter outpatient stays in the clinic, fewer adverse effects, and better patient compliance than with DLPDT alone.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"51 ","pages":"Article 104372"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0